Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNFα therapy

Scandinavian Journal of Rheumatology

Volumn 35, Issue 6, 2006, Pages 485-488

  Thonhofer, R ^a,e   Soleiman, A ^a   Kriessmayr, M ^b   Thonhofer, U ^b   Wipfler, E ^b   Gaugg, M ^d   Eder, S ^c   Erlacher, L ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

^c General Hospital of the Elizabethinans Klagenfurt ^*  (Austria)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e State Hospital Murzzuschlag   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; GOLD; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADULT ONSET STILL DISEASE; ALLERGIC REACTION; ARTHRITIS; ARTICLE; CASE REPORT; DYSPNEA; FLUSHING; FOLLOW UP; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; KIDNEY BIOPSY; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; TACHYCARDIA; TREATMENT RESPONSE; IMMUNOLOGY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; MALE; PROTEINURIA; STILL'S DISEASE, ADULT-ONSET; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947607845     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740600844688     Document Type: Article

References (15)

1. Elkon KB, Hughes GR, Bywaters EG, Ryan PF, Inman RD, Bowley NB, et al. Adult-onset Still's disease. Twenty-year followup and further studies of patients with active disease. Arthritis Rheum 1982;25:647-54.
2. Masson C, Le Loet X, Liote F, Renou P, Dubost JJ, Boissier MC, et al. Adult Still's disease. Part I. Manifestations and complications in sixty-five cases in France. Rev Rhum Engl Ed 1995;62:748-57.
3. Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still's disease: review of 228 cases from the literature. J Rheumatol 1987;14:1139-46.
4. Wendling D, Hory B, Blanc D. Adult Still's disease and mesangial glomerulonephritis. Report of two cases. Clin Rheumatol 1990;9:95-9.
5. Quemeneur T, Noel LH, Kyndt X, Droz D, Fleury D, Binaut R, et al. Thrombotic microangiopathy in adult Still's disease. Scand J Rheumatol 2005;34:399-403.
6. Kumar S, Sheaff M, Yaqoob M. Collapsing glomerulopathy in adult Still's disease. Am J Kidney Dis 2004;43:e4-10.
7. Dechant C, Schauenberg P, Antoni CE, Kraetsch HG, Kalden JR, Manger B. Long-term outcome of TNF blockade in adult-onset Still's disease. Dtsch Med Wochenschr 2004;129:1308-12.
8. Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002;46:1171-6.
9. Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987;30:186-94.
10. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30.
11. Verschueren P, Lensen F, Lerut E, Claes K, De Vos R, Van Damme B, et al. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 2003;62:368-9.
12. Wouters JM, van de Putte LB. Adult-onset Still's disease: clinical and laboratory features, treatment and progress of 45 cases. Q J Med 1986;61:1055-65.
13. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9.
14. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii13-16.
15. Brocq O, Plubel Y, Breuil V, Grisot C, Flory P, Mousnier A, et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha. Presse Med 2002;31:1836-9.